Literature DB >> 16930087

Travoprost/timolol.

Sheridan M Hoy1, Susan J Keam, Gillian M Keating.   

Abstract

Travoprost 0.004%/timolol 0.5% fixed combination (travoprost/timolol) is a once-daily eyedrops solution comprising the prostaglandin F(2alpha) analogue travoprost and the beta-adrenoceptor antagonist timolol. It is indicated for the treatment of patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-adrenoceptor antagonists or prostaglandin analogues. Once-daily travoprost/timolol had generally similar efficacy to travoprost plus timolol and was more effective than travoprost or timolol monotherapy in reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension in randomised, well designed studies. Both travoprost/timolol and latanoprost plus timolol maintained IOP control, and travoprost/timolol was shown to be noninferior to latanoprost/timolol in randomised, well designed studies. Travoprost/timolol was generally well tolerated, with a tolerability profile similar to those of travoprost plus timolol, travoprost or timolol monotherapy and latanoprost plus timolol. The majority of adverse events, such as ocular hyperaemia, were mild and resolved with or without treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930087     DOI: 10.2165/00002512-200623070-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  18 in total

1.  Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops.

Authors:  Juha-Matti Korte; Timo Kaila; K Matti Saari
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-04-26       Impact factor: 3.117

2.  In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells.

Authors:  Jean-Marc Guenoun; Christophe Baudouin; Patrice Rat; Aude Pauly; Jean-Michel Warnet; Françoise Brignole-Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-12       Impact factor: 4.799

3.  The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.

Authors:  Howard S Barnebey; Silvia Orengo-Nania; Brian E Flowers; John Samples; Sushanta Mallick; Theresa A Landry; Michael V W Bergamini
Journal:  Am J Ophthalmol       Date:  2005-07       Impact factor: 5.258

Review 4.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.

Authors:  Joel S Schuman; Gregory J Katz; Richard A Lewis; J Charles Henry; Sushanta Mallick; David T Wells; E Kenneth Sullivan; Theresa A Landry; Michael V W Bergamini; Stella M Robertson
Journal:  Am J Ophthalmol       Date:  2005-08       Impact factor: 5.258

6.  A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.

Authors:  Bret A Hughes; Jason Bacharach; E Randy Craven; Martin B Kaback; Sushanta Mallick; Theresa A Landry; Michael V W Bergamini
Journal:  J Glaucoma       Date:  2005-10       Impact factor: 2.503

Review 7.  Management of glaucoma: focus on pharmacological therapy.

Authors:  Robert E Marquis; Jess T Whitson
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

8.  Global data on visual impairment in the year 2002.

Authors:  Serge Resnikoff; Donatella Pascolini; Daniel Etya'ale; Ivo Kocur; Ramachandra Pararajasegaram; Gopal P Pokharel; Silvio P Mariotti
Journal:  Bull World Health Organ       Date:  2004-12-14       Impact factor: 9.408

9.  The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol.

Authors:  Umit Ubeyt Inan; Sitki Samet Ermis; Ayse Orman; Ersel Onrat; Aylin Yucel; Faruk Ozturk; Ali Asagidag; Atac Celik
Journal:  J Ocul Pharmacol Ther       Date:  2004-08       Impact factor: 2.671

10.  Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues.

Authors:  Najam A Sharif; Curtis R Kelly; Julie Y Crider
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-02       Impact factor: 4.799

View more
  6 in total

1.  Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations.

Authors:  Emilio Rintaro Suzuki; Cibele Lima Belico Suzuki
Journal:  Clin Ophthalmol       Date:  2010-10-21

Review 2.  Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

3.  Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction.

Authors:  Henny J M Beckers; Jan S A G Schouten; Carroll A B Webers; Rikkert van der Valk; Fred Hendrikse
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-25       Impact factor: 3.117

Review 4.  Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension.

Authors:  Monique P Curran; Jennifer S Orman
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy.

Authors:  Kenji Kashiwagi
Journal:  Jpn J Ophthalmol       Date:  2012-05-15       Impact factor: 2.447

Review 6.  Topical Medication Therapy for Glaucoma and Ocular Hypertension.

Authors:  Tao Wang; Linlin Cao; Qikun Jiang; Tianhong Zhang
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.